Primary Site >> Biliary tract Cancer
Gene >> MET
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: A link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma. PMID: 10216129 |
Ref: Characterization of a new rat cell line established from 2'AAF-induced combined hepatocellular cholangiocellular carcinoma. PMID: 11249201 Ref: Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies. PMID: 11357901 |
Ref: C-met and hepatocyte growth factor expression in combined hepatocellular and cholangiocarcinoma. PMID: 11748452 Ref: c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. PMID: 11895493 |
Ref: Intrahepatic cholangiocarcinoma in cirrhosis presents granulocyte and granulocyte-macrophage colony-stimulating factor. PMID: 14691921 |
Ref: Co-expression of cox-2, C-met and beta-catenin in cells forming invasive front of gallbladder cancer. PMID: 19956499 |
Ref: Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. PMID: 16818635 Ref: Involvement of c-Met/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met. PMID: 16950403 |
Ref: [Expressions and clinical significances of c-met, c-erbB-2, COX-2, and IL-6 in the biliary tract cancers]. PMID: 18159174 |
Ref: Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids. PMID: 18199552 Ref: c-Met targeted therapy of cholangiocarcinoma. PMID: 18494048 |
Ref: A comprehensive analysis of immunohistochemical studies in intrahepatic cholangiocarcinoma using the survival tree model. PMID: 19262069 |
Ref: Critical role of c-Met and Ki67 in progress of biliary carcinoma. PMID: 20420246 Ref: Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. PMID: 20565817 Ref: Overexpression of CD151 as an adverse marker for intrahepatic cholangiocarcinoma patients. PMID: 20715158 |
Ref: Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. PMID: 21673683 |
Ref: Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. PMID: 22178589 Ref: Significance of epithelial growth factor in the epithelial-mesenchymal transition of human gallbladder cancer cells. PMID: 22404757 Ref: The tyrosine kinase c-Met contributes to the pro-tumorigenic function of the p38 kinase in human bile duct cholangiocarcinoma cells. PMID: 23024367 |
Ref: Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PMID: 25536104 |
Ref: Prognostic Value of C-met Expression in Cholangiocarcinoma. PMID: 25873560 Ref: Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer. PMID: 27136744 |
Ref: The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC). PMID: 28638453 |
Ref: Human epidermal growth factor receptor 2, epidermal growth factor receptor, and c-MET overexpression and survival in biliary tract cancer: A meta-analysis. PMID: 29578146 Ref: PF-2341066 combined with celecoxib promotes apoptosis and inhibits proliferation in human cholangiocarcinoma QBC939 cells. PMID: 29725387 Ref: New developments in systemic therapy for advanced biliary tract cancer. PMID: 29893894 Ref: MET Activation by a Macrocyclic Peptide Agonist that Couples to Biological Responses Differently from HGF in a Context-Dependent Manner. PMID: 30322054 |